Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | NQO1 | P15559 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL7207049 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL7472 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL8906393 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819003 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL2852448 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL29665174 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL4773 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819004 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| SCHEMBL24610440 | 0.93 | ADRA2A (0.86) | ADRA2AADRA1AHTR1ACHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| EP-4234578-B1 | FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2025-11-12 | — | — | EP | claimed |
| EP-3725799-B1 | PEPTIDE BINDING TO PL-L1 AND USE THEREOF | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2025-11-05 | — | — | EP | claimed |
| US-20250326834-A1 | COMBINATION THERAPY OF CLAUDIN 18.2 ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR | SUZHOU TRANSCENTA THERAPEUTICS CO LTD (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4433510-A1 | COMBINATION THERAPY OF CLAUDIN 18.2 ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | claimed |
| EP-3541414-B1 | CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI PHARMA INC (TW) | 2024-08-28 | — | — | EP | claimed |
| EP-3380124-B1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES INC (KR) | 2024-04-03 | — | — | EP | claimed |
| EP-3947375-B1 | IMIDAZOLONYLQUINOLINE COMPOUNDS AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2024-04-03 | — | — | EP | claimed |
| EP-3484496-B1 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | UNIV SOUTHERN CALIFORNIA (US) | 2023-12-27 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| WO-2023088221-A1 | COMBINATION THERAPY OF CLAUDIN 18.2 ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2023-05-25 | — | — | WO | claimed |
| EP-3641824-B1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2022-08-31 | — | — | EP | claimed |
| EP-3539971-B1 | RUTHENIUM COMPLEXES FOR TREATING CANCER WHICH COMPRISES CANCER STEM CELLS | UNIV SANTIAGO COMPOSTELA (ES) | 2022-07-20 | — | — | EP | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | claimed |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20250367308-A1 | LIGAND-DRUG CONJUGATE OF CAMPTOTHECIN ANALOGS, INTERMEDIATES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANGHAI MICURX PHARMACEUTICAL CO.,LTD. (CN) | 2025-12-04 | — | — | US | disclosed |
| WO-2022078425-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-04-21 | — | — | WO | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367308-A1 | LIGAND-DRUG CONJUGATE OF CAMPTOTHECIN ANALOGS, INTERMEDIATES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ADGRF1, WEE1, WASF2 | ADRA2A 2818/4885ADRA1A 1680/4885HTR1A 3641/4885 |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | EGFR, CCKAR, MET | ADRA2A 572/4885ADRA1A 370/4885HTR1A 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.